Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466198 | 1.00 | DPP4 (0.59) | DPP4CHRM1MAPTDPP9FAP | |
| SCHEMBL4471195 | 1.00 | DPP4 (0.59) | DPP4CHRM1MAPTDPP9FAP | |
| SCHEMBL8270903 | 0.88 | DPP4 (0.60) | DPP4CHRM1DPP9FAP | |
| SCHEMBL4486270 | 0.87 | DPP4 (0.59) | DPP4CHRM1MAPTDPP9FAP | |
| SCHEMBL4460783 | 0.87 | DPP4 (0.59) | DPP4CHRM1MAPTDPP9FAP | |
| SCHEMBL4485715 | 0.85 | DPP4 (0.51) | DPP4CHRM1 | |
| SCHEMBL4483700 | 0.85 | DPP4 (0.51) | DPP4CHRM1 | |
| SCHEMBL4471886 | 0.83 | DPP4 (0.58) | DPP4CHRM1DPP9FAP | |
| SCHEMBL4471876 | 0.83 | DPP4 (0.58) | DPP4CHRM1DPP9FAP | |
| SCHEMBL4475662 | 0.83 | DPP4 (0.58) | DPP4CHRM1DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495002-B2 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-24 | — | — | US | disclosed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885CHRM1 318/4885MAPT 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.